Bellicum Pharmaceuticals, Inc.
BLCM
|
$0.0748
381.28%
6.1K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-82.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3229.12% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 726,826
http://www.bellicum.com
Sec Filling | Patents | 107 employees
(US) Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.
cancer immunotherapy
add to watch list Paper trade email alert is off
Brickell Biotech, Inc.
BBI
|
$2.12
16.04%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-74.2% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 6,092,806
http://www.brickellbio.com
Sec Filling | Patents | 15 employees
(US) Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.
dermatitis skin t-cell treatment ceiling
add to watch list Paper trade email alert is off
Cardiovascular Systems, Inc.
CSII
|
News
|
$20.0
-0.05%
400K
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (22.61% volume)
Earnings Calendar: 2023-05-04
Market Cap: $ 843,960,960
http://www.csi360.com
Sec Filling | Patents | 779 employees
(US) Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The firm's products are catheter-based platforms capable of treating a range of vessel sizes and plaque types. The company was founded in 1989 and is headquartered in St. Paul, MN.
cardiovascular
add to watch list Paper trade email alert is off
Checkmate Pharmaceuticals, Inc.
CMPI
|
$10.5
0.0%
|
Health Technology
(0.0% 1d) (0.2% 1m) (0.0% 1y) (0.2% 2d) (0.1% 3d) (0.0% 7d) (-49.8% volume)
Earnings Calendar: 2022-08-11
Market Cap:
http://www.checkmatepharma.com
Sec Filling | Patents | 22 employees
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.
cancer
add to watch list Paper trade email alert is off
Chembio Diagnostics, Inc.
CEMI
|
$0.455
-5.25%
350K
|
Health Technology
(0.0% 1d) (0.0% 1m) (1.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (62.64% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 16,710,265
http://www.chembio.com
Sec Filling | Patents | 324 employees
Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests that detect infectious diseases. The firm expanding its product portfolio based upon the proprietary Dual Path Platform, which uses a small drop of blood from the fingertip to provide cost-effective diagnostic results in approximately 15 minutes. Its products include human and veterinary diagnostics. The company was founded in 1985 and is headquartered in Hauppauge, NY.
infectious disease diagnostics veterinary
add to watch list Paper trade email alert is off
ChemoCentryx, Inc.
CCXI
|
$51.99
-0.04%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (160.14% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,709,791,785
http://www.chemocentryx.com
Sec Filling | Patents | 82 employees
(US) ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.
cancer autoimmunity
add to watch list Paper trade email alert is off
Chinook Therapeutics, Inc.
KDNY
|
$40.39
0.22%
-0.17%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (80.2% 1y) (0.0% 2d) (0.2% 3d) (0.0% 7d) (-30.62% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 2,900,203,021
http://www.chinooktx.com
Sec Filling | Patents | 96 employees
(US) Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.
kidney diseases kidney
add to watch list Paper trade email alert is off
Clovis Oncology, Inc.
CLVS
|
$0.0812
-3.94%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (26.22% volume)
Earnings Calendar: 2023-02-22
Market Cap: $ 11,770,367
http://www.clovisoncology.com
Sec Filling | Patents | 484 employees
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
acquisitions cancer prostate cancer liver treatment cancer treatments
Drugs
Rubraca (rucaparib)add to watch list Paper trade email alert is off
Codiak BioSciences, Inc.
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-0.9% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 2,099,289
http://www.codiakbio.com
Sec Filling | Patents | 105 employees
(United States) Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA.
diagnostics
add to watch list Paper trade email alert is off
Akouos, Inc.
AKUS
|
$13.29
1.07%
3.46%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2022-11-11
Market Cap:
http://www.akouos.com
Sec Filling | Patents | 54 employees
Akouos, Inc. engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA.
gene therapies t-cell genetic hearing loss ceiling
add to watch list Paper trade email alert is off
Albireo Pharma, Inc.
ALBO
|
$44.15
-0.23%
0.39%
1.2M
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-02-28
Market Cap: $ 913,961,644
http://www.albireopharma.com
Sec Filling | Patents | 55 employees
(US) Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. It pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
gastrointestinal liver liver disease treatment odevixibat
add to watch list Paper trade email alert is off
Allena Pharmaceuticals, Inc.
ALNA
|
$0.075
-12.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (431.58% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 9,156,242
http://www.allenapharma.com
Sec Filling | Patents | 83 employees
(United States) Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.
kidney diseases kidney stones treatment kidney
add to watch list Paper trade email alert is off
Allied Healthcare Products, Inc.
AHPI
|
$0.5501
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-66.19% volume)
Earnings Calendar:
Market Cap: $ 2,207,847
http://www.alliedhpi.com
Sec Filling | Patents | 218 employees
Allied Healthcare Products, Inc. manufactures, markets, and distributes a variety of respiratory products used in the health care industry to hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, and emergency medical product dealers. Its products include respiratory care products, medical gas equipment, and emergency medical products. The company was founded in 1979 and is headquartered in St. Louis, MO.
respiratory construction
add to watch list Paper trade email alert is off
Antares Pharma, Inc.
ATRS
|
$5.59
0.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (53.54% volume)
Earnings Calendar: 2022-08-04
Market Cap:
http://www.antarespharma.com
Sec Filling | Patents | 178 employees
(US) Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its proprietary products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ.
injection ycombinator
Drugs
Otrexup (methotrexate)XYOSTED (testosterone enanthate)
add to watch list Paper trade email alert is off
Apollo Endosurgery, Inc.
APEN
|
$10.0
0.75%
1.7M
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-53.84% volume)
Earnings Calendar: 2023-05-02
Market Cap: $ 579,719,190
http://apolloendo.com
Sec Filling | Patents | 217 employees
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, OverStitch Sx Endoscopic Suturing System, and Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas; inadvertent perforation of the GI tract; tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon; the treatment of swallowing disorders; esophageal stent fixation and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.
gastrointestinal endoscopy treatment
add to watch list Paper trade email alert is off
Applied Genetic Technologies Corporation
AGTC
|
$0.3936
1.23%
0.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-80.43% volume)
Earnings Calendar: 2022-11-08
Market Cap:
http://www.agtc.com
Sec Filling | Patents | 83 employees
(US) Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.
gene therapies genetic clinical trials
add to watch list Paper trade email alert is off
Applied Molecular Transport Inc.
AMTI
4
|
$0.263
-14.3%
-1.14%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (-22.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (10.46% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 10,871,516
http://www.appliedmt.com
Sec Filling | Patents | 80 employees
Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood and Randall J. Mrsny on November 21, 2016 and is headquartered in South San Francisco, CA.
autoimmunity metabolic treatment
add to watch list Paper trade email alert is off
Aptose Biosciences, Inc.
APTO
|
$1.3
-4.41%
-4.62%
62K
|
Health Technology
(0.0% 1d) (-6.0% 1m) (-81.2% 1y) (0.0% 2d) (0.0% 3d) (-4.1% 7d) (425.63% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 20,433,011
http://aptose.com
Sec Filling | Patents | 33 employees
(CA) Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
cancer
add to watch list Paper trade email alert is off
Aravive, Inc.
ARAV
|
$0.0401
4.74%
4M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-97.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-85.6% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 2,949,862
http://www.aravive.com
Sec Filling | Patents | 17 employees
(US) Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.
cancer t-cell ovarian cancer treatment ceiling
add to watch list Paper trade email alert is off
Athenex, Inc.
ATNX
|
$0.2031
-7.78%
1.9M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-86.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (199.02% volume)
Earnings Calendar: 2022-10-27
Market Cap: $ 1,759,498
http://www.athenex.com
Sec Filling | Patents | 574 employees
(US) Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
cancer tirbanibulin treatment
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
SNDA P 3000 | $29.61 3.35% 0.0% 30K
|
n/a
|
22:00
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
FAST P 3350 | $67.5 -1.43% -1.45% 3.6M
|
Distribution Services
|
20:00
QCRH | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
RVP P 15363 | $1.05 0.96% 0.0% 120K
|
Health Technology
|
18:00
VUZI | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
TPL P 3 | $582.4 -0.44% 0.0% 63K
|
Miscellaneous
|
15:00
RELL | $10.15 2.94% 2.86% 94K
|
Electronic Technology
|
13:30
IZEA | $2.65 4.74% 4.53% 31K
|
Technology Services
|
00:00
RKT P 383 | $11.53 1.32% 0.0% 1.6M
|
Finance
|
22:30
CTRN P 18090 | $22.28 -0.4% -0.4% 55K
|
Retail Trade
|
22:00
BRN P 10650 | $2.8 0.36% -0.36% 54K
|
Energy Minerals
|
21:00
NEOG P 10000 | $11.94 -1.65% -1.68% 2.9M
|
Health Technology
|
16:30
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10